Romiplostim and eltrombopag for immune thrombocytopenia: Methods for indirect comparison

International Journal of Technology Assessment in Health Care

Volumn 28, Issue 3, 2012, Pages 249-258

  Cooper, Katy L ^a   Fitzgerald, Patrick ^a   Dillingham, Kerry ^b   Helme, Kawitha ^b   Akehurst, Ron ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b AMGEN LTD   (United Kingdom)

Author keywords

Eltrombopag; Idiopathic thrombocytopenic purpura; Review; Romiplostim; Statistics as topic; Systematic

Indexed keywords

BAYESIAN POSTERIOR PROBABILITIES; COMPARISON METHODS; CREDIBLE INTERVAL; ELTROMBOPAG; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOGISTIC REGRESSIONS; META-ANALYSIS; MIMETICS; NON-BAYESIAN APPROACH; ODDS RATIOS; P-VALUES; PARAMETER UNCERTAINTY; PLATELET RESPONSE; ROMIPLOSTIM; SYSTEMATIC; THROMBOCYTOPENIA; THROMBOPOIETIN;

BAYESIAN NETWORKS; LOGISTICS; REVIEWS;

PLATELETS;

ELTROMBOPAG; PLACEBO; ROMIPLOSTIM;

ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BAYES THEOREM; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; LOGISTIC REGRESSION ANALYSIS; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLENECTOMY; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNCERTAINTY;

BAYES THEOREM; BENZOATES; DATABASES, FACTUAL; FEMALE; HUMANS; HYDRAZINES; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN;

EID: 84866391493     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462312000414     Document Type: Article

References (26)

1. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683-691. (Pubitemid 27341818)
2. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237-2247. (Pubitemid 350190754)
3. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672-1681. (Pubitemid 44583957)
4. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocy-topenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641-648.
5. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet. 2011;377:393-402.
6. Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 (www.cochrane-handbook.org) 2009.
7. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura inpatients with persistent low platelet counts. Arch Intern Med. 2000;160:1630-1638. (Pubitemid 30367902)
8. Evidence Review Group (ERG), Aberdeen Health Technology Assessment Group, Boyers D, et al. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP): A Single Technology Appraisal. www.nice.org.uk/guidance/index.jsp? action=download&o=49132. 2009 (accessed 30 January 2012).
9. Evidence Review Group (ERG) for Eltrombopag. Comment on the responses from GlaxoSmithKline to the appraisal committee decision and the ERG report. www.nice.org.uk/guidance/index.jsp?action= download&o=50715. 2010 (accessed 30 January 2012).
10. GlaxoSmithKline (GSK). Single Technology Appraisal (STA): Eltrom-bopag (Revolade) for the treatment of chronic immune (idiopathic) throm-bocytopenic purpura. www.nice.org.uk/guidance/index.jsp?action= download&o=49170. 2009 (accessed 30 January 2012).
11. GlaxoSmithKline (GSK). Response to Appraisal Consultation Document: Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura. http://guidance.nice.org.uk/TA/Wave17/14/FAD/CCComment. 2010 (accessed 30 January 2012).
12. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9:1-134.
13. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value in Health. 2011;14:417-428.
14. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet. 2008;371:395-403. (Pubitemid 351181334)
15. Kuter DJ, Rummel MJ, Boccia RV, et al. Comparison of splenectomy and treatment failure incidence in nonsplenectomized patient with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care: 1-year treatment and 6-month safety follow-up. Blood. 2009;114:Abstract 679.
16. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-3124. (Pubitemid 39334902)
17. Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: Evolution, critique and future directions. Stat Med. 2009;28:3049-3067.
18. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. www.nice.org.uk/aboutnice/howwework/ devnicetech/guidetothemethodsoftechnologyappraisal.jsp. 2008.
19. O'Hagan A, Luce BR, Fryback DG. A primer on Bayesian statistics in health economics and outcomes research. The Bayesian Initiative in Health Economics and Outcomes Research, and the Centre for Bayesian Statistics in Health Economics, www.shef.ac.uk/polopoly-fs/1.80637!/file/primer.pdf. 2003
20. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549-2554.
21. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-186.
22. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. 2009;113:2386-2393.
23. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145:235-244.
24. Spiegelhalter D, Thomas A, Best N, Lunn D. OpenBUGS User's Manual, Version 3.0.2. Cambridge: MRC Biostatistics Unit, Cambridge University; 2007.
25. Sutton AJ, Cooper NJ, Jones DR, et al. Evidence-based sample size calculations based upon updated meta-analysis. Stat Med. 2007;26:2479-2500. (Pubitemid 46784206)
26. Tomiyama Y, Miyakawa Y, Okamoto S, et al. Six month treatment of low dose eltrombopag is efficacious in Japanese patients with refractory chronic immune thrombocytopenic purpura (ITP). Blood. 2009;114:Ab-stract 1324.